Last reviewed · How we verify
Dengzhan Shengmai capsule
Dengzhan Shengmai capsule, marketed by Guangzhou University of Traditional Chinese Medicine, holds a position in the traditional Chinese medicine segment for its primary indication. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk lies in the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Dengzhan Shengmai capsule |
|---|---|
| Also known as | DZSM |
| Sponsor | Guangzhou University of Traditional Chinese Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: